AFT Pharmaceuticals Limited (AFP) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

I would now like to hand the conference over to Hartley Atkinson, CEO. Please go ahead. Hartley Atkinson Thank you very much and thank you everyone for joining our call today. What we'll do is we'll go through the presentation and then as has been mentioned have time for questions afterwards. I'll just read out the page numbers as well so that everyone knows where we're at in terms of the presentation pages. So look, first page obviously and then the second page is the disclaimer which I assume everyone is well aware of and has read. Moving now to page three which is just look a brief summary of kind of where we're at. We have our established Australia New Zealand business, pleased to have good sales growth of 23% across both Australia and New Zealand. Certainly Australia was very solid with 31% growth. New Zealand as well though grew at 8% and the OTC business which is the front end higher margin consumer business still grew at 12% so we're still getting good performance in the New Zealand market. And then looking across to the box on the right at the top, what we are putting a lot of work in at the moment is continuing to expand our global footprint, so Europe, the UK and the EU, North America, US, Canada, then Asia, doing a lot of work on there, including China, but not just China, we have Singapore, Malaysia, Hong Kong, Korea, and then also South Africa, a lot of work has gone into that business over the last few months. And then looking down the second row, certainly the innovative R&D pipeline It's still a really important part of our business going forward. We have made good progress as well with our big project for off-patent injectables. But actually, interestingly, we're working hard on a project that will also add IP to this as well. And we're hoping to be...